Type 1 diabetes is a chronic autoimmune disease that affects millions of people worldwide, but a groundbreaking new therapy is offering hope for those living with the condition. Known as the first therapy to target the disease process itself, rather than just the symptoms, this innovative treatment is poised to revolutionize diabetes care. In this article, we will explore the science behind this new therapy and the potential it holds for the future of diabetes treatment.
The first patient to receive a breakthrough drug that delays the onset of Type 1 diabetes (T1D) in Colorado is a 16-year-old boy called Erik Aeling. Erik ran a higher risk of developing the autoimmune disease because of a genetic link, prompting his parents to have him screened at the Barbara Davis Center for Diabetes. Although positive for the autoantibodies that signify the gradual onset of diabetes, Erik was diagnosed differently and targeted for an innovative new drug called Tzield, which has just gained FDA approval. Tzield delays the onset of the disease by attacking and binding to CD3 markers on the surface of T cells that attack the beta cells in a patient’s pancreas, which produce insulin, as part of the T1D process. Kimber Simmons, MD, assistant professor of pediatrics at the University of Colorado School of Medicine, explained that Tzield targets the “bad” T cells in a patient’s pancreas, while giving healthy T cells time to multiply and “restore order” for a brief period of time. Although not a cure, some patients have lived for years without requiring clinical treatment.
BDC was actively involved in the trial that led to Tzield’s approval, housed the study in its state-of-the-art therapeutic facilities, and worked closely with the key members of the trial team. The center is also part of a wider national consortium to increase screening and gain deeper understanding into this disease, TrialNet, which is funded by the National Institute of Diabetes and Digestive and Kidney Diseases. Andrea Steck, MD, leads the work with TrialNet, and the center is a site for all its main prevention trials. Tzield is currently approved only for stage-two patients who are at least eight years old.
“This is so significant, because it opens the door to preventative therapies,” Professor Simmons commented. “This is the first thing we have which has a real potential to intervene in the disease process.”
Type 1 diabetes is an autoimmune disorder in which the immune system attacks and damages the insulin-producing cells of the pancreas. It is usually diagnosed in children or young adults, happens suddenly and requires lifelong management with insulin injections. Tzield is a new and optimistic breakthrough for patients like Erik, who supports this research and is grateful that he can “divert” his path. His family have also been committed patients at the Barbara Davis Center since his sister’s diagnosis of T1D in 2016, which caused a dangerous complication called diabetic ketoacidosis. The family established the importance of screening, and the center has screened more than 33,000 children through the Autoimmunity Screening for Kids Study in the United States.
In conclusion, the discovery of a new therapy to specifically target the disease process of Type 1 diabetes is extremely promising. This development, if successful, could drastically improve the lives of millions of individuals living with Type 1 diabetes around the world. With advancements like this, we can hope for a future where this disease is no longer a daily burden for those affected. The medical field is constantly pushing boundaries and finding new ways to improve patient outcomes, and this breakthrough is just one example of the tremendous potential for progress in the years to come. It’s an exciting time to be a part of the world of medicine, and we eagerly await further developments and progress in the fight against Type 1 diabetes.
:format(jpeg):fill(f8f8f8,true)/s3/static.nrc.nl/images/gn4/stripped/data99303144-01a7fe.png "Puzzle: Solve the Crossword and Test Your Knowledge")